Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bill.com Holdings Inc (BILL) vs Boston Scientific Corporation (BSX) Price & Performance

Bill.com Holdings IncTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Bill.com Holdings Inc vs Boston Scientific Corporation — how do they compare? Bill.com Holdings Inc trades at $42.93 (market cap $4.12B), while Boston Scientific Corporation trades at $42.62 (market cap $66.37B). The key difference: Boston Scientific Corporation is far larger — about 16.1× Bill.com Holdings Inc's market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

BILLBSX
Market Cap
$4.12B$66.37B
Sector
TechnologyHealth
52-Week High
$56.32$108.14
52-Week Low
$31.96$42.63
Enterprise Value
$3.83B$75.94B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bill.com Holdings Inc

BILL Holdings trades at $42.86, up 3.63% today, with strong technical momentum and bullish analyst sentiment. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.68 surpassing the $0.55 estimate. Revenue growth is robust, rising from $642M in 2022 to $1.46B in 2025, though net margins remain thin at 0.01%. Recent leadership changes and a $1B buyback program signal strategic focus on growth and shareholder value.

Outlook is positive with a consensus price target of $48.00 implying 12% upside, supported by 56% analyst buy ratings. Key risks include high valuation multiples (P/E 213.91), competitive pressures in SaaS, and sensitivity to small business economic health. Cash flow trends show operational improvement, but investing outflows remain elevated.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.

BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.

Returns comparison

Trailing returns across standard periods

About Bill.com Holdings Inc

Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.

Read more on BILL

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX